S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   355.06 (-1.72%)
AAPL   171.55 (-1.27%)
MSFT   313.95 (-2.44%)
META   300.11 (-2.19%)
GOOGL   132.20 (-1.47%)
AMZN   125.00 (-3.45%)
TSLA   247.59 (-1.59%)
NVDA   436.04 (-2.63%)
NIO   8.66 (-1.48%)
BABA   84.48 (-2.37%)
AMD   100.08 (-3.09%)
T   14.62 (-0.34%)
F   12.06 (-2.03%)
MU   67.90 (-0.09%)
CGC   0.68 (-7.45%)
GE   107.07 (-1.58%)
DIS   79.62 (-2.51%)
AMC   7.89 (-3.19%)
PFE   33.89 (-0.15%)
PYPL   57.69 (-1.49%)
NFLX   378.68 (-0.43%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   355.06 (-1.72%)
AAPL   171.55 (-1.27%)
MSFT   313.95 (-2.44%)
META   300.11 (-2.19%)
GOOGL   132.20 (-1.47%)
AMZN   125.00 (-3.45%)
TSLA   247.59 (-1.59%)
NVDA   436.04 (-2.63%)
NIO   8.66 (-1.48%)
BABA   84.48 (-2.37%)
AMD   100.08 (-3.09%)
T   14.62 (-0.34%)
F   12.06 (-2.03%)
MU   67.90 (-0.09%)
CGC   0.68 (-7.45%)
GE   107.07 (-1.58%)
DIS   79.62 (-2.51%)
AMC   7.89 (-3.19%)
PFE   33.89 (-0.15%)
PYPL   57.69 (-1.49%)
NFLX   378.68 (-0.43%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   355.06 (-1.72%)
AAPL   171.55 (-1.27%)
MSFT   313.95 (-2.44%)
META   300.11 (-2.19%)
GOOGL   132.20 (-1.47%)
AMZN   125.00 (-3.45%)
TSLA   247.59 (-1.59%)
NVDA   436.04 (-2.63%)
NIO   8.66 (-1.48%)
BABA   84.48 (-2.37%)
AMD   100.08 (-3.09%)
T   14.62 (-0.34%)
F   12.06 (-2.03%)
MU   67.90 (-0.09%)
CGC   0.68 (-7.45%)
GE   107.07 (-1.58%)
DIS   79.62 (-2.51%)
AMC   7.89 (-3.19%)
PFE   33.89 (-0.15%)
PYPL   57.69 (-1.49%)
NFLX   378.68 (-0.43%)
S&P 500   4,230.72 (-1.34%)
DOW   33,050.25 (-1.15%)
QQQ   355.06 (-1.72%)
AAPL   171.55 (-1.27%)
MSFT   313.95 (-2.44%)
META   300.11 (-2.19%)
GOOGL   132.20 (-1.47%)
AMZN   125.00 (-3.45%)
TSLA   247.59 (-1.59%)
NVDA   436.04 (-2.63%)
NIO   8.66 (-1.48%)
BABA   84.48 (-2.37%)
AMD   100.08 (-3.09%)
T   14.62 (-0.34%)
F   12.06 (-2.03%)
MU   67.90 (-0.09%)
CGC   0.68 (-7.45%)
GE   107.07 (-1.58%)
DIS   79.62 (-2.51%)
AMC   7.89 (-3.19%)
PFE   33.89 (-0.15%)
PYPL   57.69 (-1.49%)
NFLX   378.68 (-0.43%)
Idea EngineIdea Engine
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Forecast, Price & News

$11.28
+0.25 (+2.27%)
(As of 11:57 AM ET)
Compare
Today's Range
$10.94
▼
$11.29
50-Day Range
$11.03
▼
$13.86
52-Week Range
$9.10
▼
$14.10
Volume
632,250 shs
Average Volume
2.37 million shs
Market Capitalization
$3.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.17
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
45.4% Upside
$16.17 Price Target
Short Interest
Bearish
6.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.76mentions of Amicus Therapeutics in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to $0.11 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

473rd out of 975 stocks

Pharmaceutical Preparations Industry

211th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Price History

FOLD Stock News Headlines

October 3, 2023 | finance.yahoo.com
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 2, 2023 | americanbankingnews.com
Equities Analysts Issue Forecasts for Amicus Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:FOLD)
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
October 1, 2023 | americanbankingnews.com
Amicus Therapeutics (NASDAQ:FOLD) PT Raised to $19.00 at Bank of America
October 1, 2023 | americanbankingnews.com
Amicus Therapeutics (NASDAQ:FOLD) PT Raised to $19.00
September 30, 2023 | thestreet.com
Amicus Therapeutics (FOLD) Stock Drops as FDA Requests More Data on Drug Candidate
September 30, 2023 | msn.com
JP Morgan Maintains Amicus Therapeutics (FOLD) Overweight Recommendation
September 30, 2023 | americanbankingnews.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up on Analyst Upgrade
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 30, 2023 | markets.businessinsider.com
Amicus Therapeutics : FDA Approves Pombiliti + Opfolda 65mg Capsules For Late-onset Pompe Disease
September 30, 2023 | reuters.com
Amicus' muscle disorder therapy gets US FDA nod but restricted label drags shares
September 29, 2023 | bizjournals.com
Lab Notes: Amicus gets FDA approval for muscle therapy; Aro Biotherapeutics recieves rare pediatric drug designation
September 29, 2023 | finance.yahoo.com
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
September 28, 2023 | finance.yahoo.com
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023 | finance.yahoo.com
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023 | finance.yahoo.com
UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatment
September 28, 2023 | benzinga.com
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
September 28, 2023 | americanbankingnews.com
Amicus Therapeutics, Inc. to Post Q3 2024 Earnings of $0.05 Per Share, Zacks Research Forecasts (NASDAQ:FOLD)
September 28, 2023 | americanbankingnews.com
Zacks Research Weighs in on Amicus Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:FOLD)
September 22, 2023 | stocknews.com
Moderna (MRNA) and 2 More Biotech Stocks That Are Worth Watching
September 1, 2023 | stocknews.com
Which of These 3 Biotech Stocks Are a Buy, Sell, or Hold?
September 1, 2023 | finance.yahoo.com
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
August 29, 2023 | finance.yahoo.com
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 25, 2023 | seekingalpha.com
Amicus Therapeutics: U.K. Approval Expands Global Reach
August 21, 2023 | markets.businessinsider.com
Amicus Therapeutics Names Simon Harford New CFO With Immediate Effect
August 16, 2023 | finance.yahoo.com
Amicus Therapeutics Inc (AM6.SG)
August 15, 2023 | finance.yahoo.com
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
8/08/2023
Today
10/03/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
CIK
1178879
Web
www.amicusrx.com
Phone
(215) 921-7600
Fax
609-662-2001
Employees
484
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$16.17
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+46.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-236,570,000.00
Net Margins
-52.85%
Pretax Margin
-55.06%
Return on Equity
-157.79%
Return on Assets
-25.43%

Debt

Debt-to-Equity Ratio
3.53
Current Ratio
2.72
Quick Ratio
2.40

Sales & Book Value

Annual Sales
$329.23 million
Price / Sales
9.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.44 per share
Price / Book
25.07

Miscellaneous

Outstanding Shares
287,120,000
Free Float
281,091,000
Market Cap
$3.17 billion
Optionable
Optionable
Beta
0.86

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. John F. CrowleyMr. John F. Crowley (Age 56)
    Exec. Chairman
    Comp: $1.88M
  • Mr. Bradley L. Campbell M.B.A.Mr. Bradley L. Campbell M.B.A. (Age 47)
    CEO, Pres & Director
    Comp: $984.09k
  • Ms. Ellen S. Rosenberg (Age 60)
    Chief Legal Officer & Corp. Sec.
    Comp: $733.94k
  • Mr. David M. Clark (Age 48)
    Chief People Officer
    Comp: $701.39k
  • Ms. Daphne E. Quimi CPA (Age 57)
    M.B.A., Sr. VP of Fin.
    Comp: $748.4k
  • Dr. Jeffrey P. Castelli (Age 51)
    Chief Devel. Officer
    Comp: $709.64k
  • Mr. Simon Nicolas Reade Harford (Age 62)
    Chief Financial Officer
  • Ms. Samantha Prout (Age 45)
    Chief Accounting Officer & Controller
  • Dr. Jill Weimer Ph.D.
    Chief Science Officer
  • Andrew Faughnan
    Sr. Director of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

6 brokers have issued twelve-month target prices for Amicus Therapeutics' stock. Their FOLD share price forecasts range from $11.00 to $19.00. On average, they expect the company's stock price to reach $16.17 in the next year. This suggests a possible upside of 46.6% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2023?

Amicus Therapeutics' stock was trading at $12.21 on January 1st, 2023. Since then, FOLD shares have decreased by 9.7% and is now trading at $11.03.
View the best growth stocks for 2023 here.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FOLD earnings forecast.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The biopharmaceutical company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $89.57 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 157.79% and a negative net margin of 52.85%.

What ETFs hold Amicus Therapeutics' stock?

ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $11.03.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.17 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 484 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -